Sarah Scagliarini, Oncology Specialist at Antonio Cardarelli National Hospital, shared a post on LinkedIn:
“Grand finale for Nivolumab plus Cabozantinib in 1 line for mccRCC. Checkmate 9ER final analysis in press on Annals of Oncology.”
Sarah Scagliarini/LinkedIn